REZOLUTE INC (RZLT)
Health Care · biotechnology · NASDAQ
Rezolute is a late-stage biotech developer of ersodetug, an insulin receptor-targeting antibody aimed at treating rare forms of refractory hypoglycemia.
What REZOLUTE INC does
Rezolute, Inc. is a late-stage biopharmaceutical company focused on developing therapies for refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI). Its lead clinical asset, ersodetug, is an intravenously administered human monoclonal antibody designed to modulate insulin receptor activity.
Recent developments
The FDA is currently reviewing additional datasets for ersodetug in congenital HI following the sunRIZE study's missed primary endpoint. Meanwhile, the company is progressing its Phase 3 upLIFT study for tumor HI, with topline results expected by the end of 2026.
From REZOLUTE INC's filing of 2026-09-24.
Themes: rare disease therapeutics, endocrinology, hyperinsulinism, hypoglycemia management, monoclonal antibody therapy
Fundamentals
- Price$4.64 as of 2026-10-08 close
- Market cap$449M as of 2026-09-21 (share count; price 2026-10-08)
- 1-year return-46.8% 2025-10-08 close $8.72 → 2026-10-08 close $4.64
- P/En/a negative earnings
- ROE-77.1% FY2026, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Beta0.99 as of 2026-09-02
- Last reported earnings2026-09-24 SEC EDGAR Form 8-K (Item 2.02)
How RZLT compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How REZOLUTE INC looks technically
REZOLUTE INC (RZLT) is trading 24.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 43 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-08-31, pushing above its recent trading range. It is 59.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 24.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +24.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.46 | $4.46 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.74 | $3.74 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 20 calendar days ago — the swings before that are what the structure reading is measured on | 20 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 43 trading days ago — a "golden cross", a bullish long-term signal | 43 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 24.2% above | +24.2% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend) | 20.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30) | 62.2 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($3.73 to $4.68) — its "stochastic" reading is 95 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 95.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $11.46 | $11.46 |
|---|---|---|
| From the 52-week high | it is 59.5% below its 52-week high (its highest price of the past year) | -59.5% |
| Above the 52-week low | it is 333.6% above its 52-week low (its lowest price of the past year) | +333.6% |
| Below the 52-week high | it is 59.5% below its highest point of the past year | 59.5% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-08-31, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 15 trading days ago | 15 sessions |
| All-time high | its highest closing price on record is $750.00 (set on 2013-01-23) | $750.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.40 to $10.94), and it has recovered roughly a third of its fall from last year’s high — 34% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.30 to $7.60. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. Worth noting that the whole move happened in 1 day, so it is a narrow thing to be measuring a retracement against. | 34.0% |
| From the all-time high | it is 99.4% below its all-time high | -99.4% |
| Nearest price level | it is trading 0.5% below a resistance level at $4.67 — a price it turned at three times since 2024-11-19, most recently on 2026-06-04. Since 2024-10-08 it has 7 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.5% |
| All-time low | its lowest closing price on record is $0.72 (set on 2023-11-10) | $0.72 |
| Above the all-time low | it is 544.4% above its all-time low | +544.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 42nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3174 between its high and its low — about 6.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3174 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.73 and $4.50 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.73 – $4.12 – $4.50 |
| Typical daily range (% of price) | its price moves about 6.8% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.8% |
| Stretch from the 200-day average | it is trading 2.9 daily ranges above its 200-day average price (24.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.40× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 9.2% since the prior reading | +9.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.24 toward buy |
Candlestick patterns
1
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.1% |
|---|---|---|
| Gap filled | a 7.2% gap up opened on 2026-10-06 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +7.41% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 4.4 percentage points (the stock gained 5.5% while the market gained 1.0%) | +4.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 10.3 percentage points (the stock lost 6.5% while the market gained 3.8%) | -10.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 24.9 percentage points (the stock gained 42.3% while the market gained 17.5%) | +24.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 61.8 percentage points (the stock lost 46.8% while the market gained 15.0%) | -61.8% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.1% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.1% of the share price. | -5.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 29% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $3.59 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | +29.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 11% above the average price paid since it last reported on 2026-09-24 (its 10-K), so the typical buyer over that stretch is showing a gain. That average is $4.19 — a volume-weighted average of daily closes over 11 sessions, not a true tick-by-tick VWAP. | +10.8% |
Price levels it has turned at before
RZLT last closed at $4.64 on 2026-10-08. Since 2024-10-08 it has turned at 7 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.67 | Resistance | 0.5% above the last close | turned there three times · 2024-11-19 to 2026-06-04 |
| $4.44 | Support | 4.4% below the last close | turned there three times · 2025-01-16 to 2026-08-14 |
| $4.31 | Support | 7.2% below the last close | turned there twice · 2025-04-23 to 2025-05-21 |
| $4.10 | Support | 11.6% below the last close | turned there three times · 2024-12-18 to 2026-07-17 |
| $5.24 | Resistance | 12.9% above the last close | turned there twice · 2024-10-31 to 2026-08-04 |
| $5.41 | Resistance | 16.5% above the last close | turned there twice · 2026-07-01 to 2026-07-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · Analyst price target recently RAISED · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.36 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$9.10 range $6.00 – $14.00; median $9.50
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RZLT
- Consensus EPS estimate-$0.1812 next reporting period, as of 2026-10-05
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company faces significant uncertainty regarding the regulatory path forward for its lead candidate, ersodetug, for congenital hyperinsulinism following the failure of its Phase 3 sunRIZE study to meet primary endpoints.","The company's clinical development, commercialization, and operational plans are highly dependent on successful regulatory outcomes and the receipt of additional capital."]
What changed in the latest 10-Q
AI-assisted comparison of RZLT's 10-Q filed 2026-05-12 against the prior one filed 2026-02-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing specifies company focus on 'therapies that substantially improve the quality of life for individuals living with hyperinsulinism' with 'alleviating the burden of severe and debilitating hypoglycemia' (filed 2026-05-12)
- Newer filing narrows priorities to 'second half of 2026' and removes reference to two Phase 3 programs, focusing only on congenital HI and upLIFT (filed 2026-05-12)
- Newer filing adds detailed description of CGM secondary endpoint: 'larger and often nominally statistically significant glycemic improvements compared to placebo were consistently observed throughout the maintenance dosing phase' (filed 2026-05-12)
- Newer filing adds section 'Summary of Key Additional Data Presented' with specific quantitative results for CGM-based outcomes including percentage reductions and increases (filed 2026-05-12)
- Newer filing documents FDA meeting on March 17, 2026, with specific discussion points and FDA's acknowledgment of behavioral factors and SMBG limitations (filed 2026-05-12)
- Newer filing states FDA 'encouraged us to submit comprehensive analysis datasets' and describes potential outcomes including marketing application submission or need for additional studies (filed 2026-05-12)
- Newer filing updates OLE exposure duration to '~24 months' maximum for older patients (filed 2026-05-12)
- Newer filing specifies 'rolled-over placebo participants' showed 'clinically significant change in glycemic control' compared to controlled period (filed 2026-05-12)
- Newer filing documents OLE benefits include 'concurrent significant overall reduction in background SOC therapies' with specific examples (diazoxide, somatostatin analogs, tube feeds) (filed 2026-05-12)
- Removed:
- Older filing states company is 'focused on developing biologics' (filed 2026-02-12); newer filing removes 'biologics' descriptor
- Older filing includes 'progress our two Phase 3 programs in congenital and tumor hyperinsulinism' as priority (filed 2026-02-12); newer filing removes reference to dual programs in opening priorities
- Older filing states priorities for 'all of 2026' (filed 2026-02-12); newer filing narrows to 'second half of 2026'
- Older filing includes goal to 'complete enrollment in the registrational tumor HI study and announce topline data from the registrational tumor HI study' (filed 2026-02-12); newer filing removes these tumor HI goals from priority section
- Older filing describes study endpoint results as 'reductions from baseline in events and time in hypoglycemia in both treatment groups, but not enough to be statistically significant' (filed 2026-02-12); newer filing removes this general statement
- Older filing uses phrase 'particularly for hypoglycemia events by self-monitored glucometer' (filed 2026-02-12); newer filing uses 'SMBG' and adds more technical description
- Older filing states 'While additional analyses are ongoing' (filed 2026-02-12); newer filing removes this phrase
- Older filing references meeting 'prior to the end of calendar Q1 2026' (filed 2026-02-12); newer filing documents meeting already occurred on March 17, 2026
- Older filing states 'FDA may require additional clinical studies' (filed 2026-02-12); newer filing states FDA 'encouraged us to submit comprehensive analysis datasets' first
- Older filing reports OLE exposure duration maximum of '~21 months' (filed 2026-02-12); newer filing updates to '~24 months'
- Reworded:
- Older filing: 'hypoglycemia-avoidant confounding behaviors' (filed 2026-02-12); Newer filing: 'unblinded nature of SMBG necessary for patient standard of care, along with perceptions of treatment assignment' (filed 2026-05-12)
- Older filing: 'assessing the potential benefit in the ongoing open-label extension portion of the study will be important' (filed 2026-02-12); Newer filing: presents actual OLE data and observations (filed 2026-05-12)
- Older filing: 'We believe that a potential indicator of ersodetug's underlying efficacy is an observed reduction in overall background standard of care therapies' (filed 2026-02-12); Newer filing: 'These glycemic benefits have enabled a concurrent significant overall reduction in background SOC therapies...which we believe is a potential indicator of ersodetug's underlying efficacy' (filed 2026-05-12)
- Older filing: 'several children who have discontinued SOC and tube feeds' (filed 2026-02-12); Newer filing: 'a significant number of patients now receiving ersodetug as monotherapy' (filed 2026-05-12)
- Older filing describes placebo response as 'a surprise to us' (filed 2026-02-12); Newer filing describes it as 'unexpected' (filed 2026-05-12)
- Older filing: 'intensive visits and monitoring is inevitable' (filed 2026-02-12); Newer filing: 'the unblinded nature of SMBG necessary for patient standard of care' with more technical framing (filed 2026-05-12)
- Notes:
- Text comparison limited to MD&A sections provided; full 10-Q filings not fully assessed
- Section was truncated in older filing; comparison based on complete text available in newer filing
- Newer filing includes May 1, 2026 presentation details not yet available in older filing dated February 12, 2026
Risk Factors
- Added:
- Reference to 'Part II, Item 1A of our Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2025 filed with the SEC on February 12, 2026' added to Risk Factors introduction (filed 2026-05-12)
- Nine months ended March 31, 2026 balance sheet data (filed 2026-05-12)
- Nine months ended March 31, 2026 statements of operations and comprehensive loss (filed 2026-05-12)
- Nine months ended March 31, 2026 statements of shareholders' equity (filed 2026-05-12)
- Nine months ended March 31, 2026 statements of cash flows (filed 2026-05-12)
- Removed:
- Six months ended December 31, 2025 and 2024 balance sheet data (filed 2026-02-12)
- Six months ended December 31, 2025 and 2024 statements of operations and comprehensive loss (filed 2026-02-12)
- Six months ended December 31, 2025 and 2024 statements of shareholders' equity (filed 2026-02-12)
- Six months ended December 31, 2025 and 2024 statements of cash flows (filed 2026-02-12)
- Reworded:
- Balance sheet as of date changed from December 31, 2025 to March 31, 2026 (filed 2026-05-12)
- Statement of operations period changed from 'Three Months Ended December 31' and 'Six Months Ended December 31' to 'Three Months Ended March 31' and 'Nine Months Ended March 31' (filed 2026-05-12)
- Statement of shareholders' equity period changed from 'Six Months Ended December 31, 2025 and 2024' to 'Nine Months Ended March 31, 2026 and 2025' (filed 2026-05-12)
- Cash flows statement period changed from 'Six Months Ended December 31' to 'Nine Months Ended March 31' (filed 2026-05-12)
- Notes:
- The two filings cover different fiscal periods: the older filing (2026-02-12) covers the six months ended December 31, 2025, while the newer filing (2026-05-12) covers the nine months ended March 31, 2026
- Financial statement amounts differ materially between the two filings due to the different reporting periods and dates
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
Cluster buying: 5 different insiders reported open-market purchases (SEC code P) of RZLT within a 30-day window between 2025-12-15 and 2025-12-16. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-03-30. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RZLT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding RZLT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 10,429,716
- Reported value $54,234,523
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about RZLT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
RZLT had 16,814,402 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
RZLT had 17.4% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 14.84 days to cover at the same settlement.
- Reported short interest (shares) 16,814,402
- Short interest (% of shares outstanding) 17.4%
- Prior settlement (shares) 16,998,710
- Reported change -1.08%
- Days to cover (reported) 14.84
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Xeris Biopharma (XERS)
- Zealand Pharma (ZEAL)
- Amgen (AMGN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RZLT vs…
REZOLUTE INC is found in…
RZLT ranks in…
Frequently asked questions
What does REZOLUTE INC (RZLT) do?
Rezolute, Inc. is a late-stage biopharmaceutical company focused on developing therapies for refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI). Its lead clinical asset, ersodetug, is an intravenously administered human monoclonal antibody designed to modulate insulin receptor activity.
What sector is REZOLUTE INC (RZLT) in?
REZOLUTE INC (RZLT) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are REZOLUTE INC's (RZLT) competitors?
Notable peers of REZOLUTE INC (RZLT) include Xeris Biopharma, Zealand Pharma and Amgen. This peer set is informational only — not financial advice.
Is REZOLUTE INC (RZLT) overbought or oversold right now?
REZOLUTE INC (RZLT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 62, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RZLT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.